REZOLUTE, INC. Current Liabilities
REZOLUTE, INC. (RZLT) had Current Liabilities of $11.42 million as of 2026-06-30, per its 10-K filed 2026-09-24.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-09-24
- 2026-06-30: Liabilities, Current $11.42M.
- 2026-03-31: Liabilities, Current $7.70M.
- 2025-12-31: Liabilities, Current $9.53M.
- 2025-09-30: Liabilities, Current $10.21M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $11.42M 10-K · filed 2026-09-24 | |
| 2026-03-31 | $7.70M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $9.53M 10-Q · filed 2026-02-12 | |
| 2025-09-30 | $10.21M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $11.91M 10-K · filed 2026-09-24 | |
| 2025-03-31 | $10.53M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $10.61M 10-Q · filed 2025-02-12 | |
| 2024-09-30 | $7.99M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $9.61M 10-K · filed 2025-09-17 | |
| 2024-03-31 | $6.96M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $8.01M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $7.20M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $5.20M 10-K · filed 2024-09-19 | |
| 2023-03-31 | $4.39M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $6.31M 10-Q · filed 2023-02-10 | |
| 2022-09-30 | $2.43M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $2.46M 10-K · filed 2023-09-14 | |
| 2022-03-31 | $2.88M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $6.45M 10-Q · filed 2022-02-09 | |
| 2021-09-30 | $2.60M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $1.97M 10-K · filed 2022-09-15 | |
| 2021-03-31 | $3.59M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $2.73M 10-Q · filed 2021-02-10 | |
| 2020-09-30 | $2.92M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $3.23M 10-K · filed 2021-09-15 | |
| 2020-03-31 | $3.53M 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $5.54M 10-Q · filed 2020-02-12 | |
| 2019-09-30 | $5.52M 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $8.38M 10-K · filed 2020-10-13 | |
| 2019-03-31 | $6.62M 10-Q · filed 2019-05-10 | |
| 2018-12-31 | $2.98M 10-Q · filed 2019-02-14 | |
| 2018-09-30 | $7.34M 10-Q · filed 2018-12-14 | |
| 2018-06-30 | $6.25M 10-K · filed 2019-09-10 | $6.25M 10-K · filed 2018-10-15 |
| 2018-03-31 | $4.37M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $2.25M 10-Q · filed 2018-02-14 | |
| 2017-09-30 | $1.69M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $1.77M 10-K · filed 2018-10-15 | |
| 2017-03-31 | $2.02M 10-Q · filed 2017-05-15 | |
| 2016-12-31 | $1.67M 10-Q · filed 2017-02-02 | |
| 2016-09-30 | $1.49M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $1.73M 10-K · filed 2017-09-22 | |
| 2016-03-31 | $2.42M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $2.49M 10-Q · filed 2016-02-16 | |
| 2015-09-30 | $1.96M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $1.71M 10-K · filed 2016-09-28 | |
| 2015-03-31 | $1.80M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $2.37M 10-Q · filed 2015-02-17 | |
| 2014-09-30 | $892.91K 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $964.04K 10-K · filed 2015-09-28 | |
| 2014-03-31 | $2.86M 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $6.54M 10-Q · filed 2014-02-13 | |
| 2013-09-30 | $5.68M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $5.27M 10-K · filed 2014-09-30 | |
| 2013-03-31 | $5.12M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $24.47K 10-Q · filed 2013-02-14 | |
| 2012-09-30 | $15.64K 10-Q · filed 2012-11-19 | |
| 2012-06-30 | $2.36M 10-K · filed 2013-09-11 | $10.55K 10-K/A · filed 2012-11-09 |
| 2012-03-31 | $8.85K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $1.40M 10-K · filed 2013-09-11 | $5.87K 10-Q · filed 2012-02-14 |
| 2011-09-30 | $5.50K 10-Q/A · filed 2011-12-13 | |
| 2011-06-30 | $11.66K 10-K/A · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |